Page 22 - NAMAH-Apr-2018

Namah Vol. 26, Issue 1, 24th April 2018

Curcumin nanoparticles To examine the in vitro
were found to be more cytotoxic activity of cell
effective than curcumin in death of curcumin and
exerting anti-proliferative nanocurcumin on human
effect against breast cancer breast adenocarcinoma
cells. cell line (MDA-MB231).

It also prevented metastasis Cytotoxicity and
of breast cancer cells (15). viability of curcumin
and nanocurcumin
were assessed by
3-(4,5-dimethylthiazol-
2-yl)-2,5-
diphenyltetrazolium
bromide (MTT) and dye
exclusion assay.
Research by Saab et al. In mammalian, non-
highlights that curcumin may malignant HMEC
be beneficial in treatment 184A1 and cancerous
of non-malignant or benign MCF-7 cells during
breast tumours as well. curcumin treatment
were investigated by
A study published in utilising multiphoton,
Anticancer Research 2005, fluorescence, and
demonstrates that curcumin atomic force (AFM)
regulates as many as 30 microscopies.
genes and acts on multiple
biochemical pathways in
order to destroy breast
cancer cells (16).
3 weeks Researchers have identified 6000mg. per day for 7
dosing for advanced consecutive days every
metastatic breast cancer at 3 weeks along with
6000 mg and concomitant standard docetaxel
use with chemotherapy (17). treatment.
Topical treatment helped An ethanol extract of
with external breast cancer turmeric (Curcuma longa)
lesions. 90% of individuals as well as an ointment
experienced a reduction in of curcumin (its active
smell. Itching reduced in ingredient) were found
almost all cases. 70% of to produce remarkable

22